Kyverna Therapeutics (KYTX) News Today $3.22 -0.24 (-6.94%) Closing price 04:00 PM EasternExtended Trading$3.22 0.00 (0.00%) As of 05:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KYTX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period 3 Promising Penny Stocks With Market Caps Over $100MJune 10 at 6:06 PM | finance.yahoo.comKyverna Therapeutics, Inc. (NASDAQ:KYTX) Short Interest Up 20.6% in MayKyverna Therapeutics, Inc. (NASDAQ:KYTX - Get Free Report) was the target of a large growth in short interest in the month of May. As of May 15th, there was short interest totalling 2,580,000 shares, a growth of 20.6% from the April 30th total of 2,140,000 shares. Based on an average daily trading volume, of 307,600 shares, the days-to-cover ratio is currently 8.4 days. Currently, 13.2% of the company's shares are sold short.June 4, 2025 | marketbeat.comContrasting Kyverna Therapeutics (NASDAQ:KYTX) and Invivyd (NASDAQ:IVVD)June 3, 2025 | americanbankingnews.comKyverna Therapeutics, Inc. (NASDAQ:KYTX) Shares Sold by Millennium Management LLCMillennium Management LLC lessened its holdings in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) by 40.4% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 746,521 shares of the company's stock after selling 507,035 shJune 1, 2025 | marketbeat.comKyverna Therapeutics to Present at the Jefferies Global Healthcare ConferenceMay 28, 2025 | prnewswire.comKyverna Therapeutics (NASDAQ:KYTX) Stock Rating Upgraded by HC WainwrightHC Wainwright upgraded shares of Kyverna Therapeutics from a "neutral" rating to a "buy" rating and lifted their price objective for the company from $4.00 to $5.00 in a research note on Tuesday.May 28, 2025 | marketbeat.comHC Wainwright & Co. Upgrades Kyverna Therapeutics (KYTX)May 27, 2025 | msn.comHC Wainwright Issues Pessimistic Forecast for KYTX EarningsKyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) - Research analysts at HC Wainwright reduced their Q2 2025 earnings per share (EPS) estimates for Kyverna Therapeutics in a report released on Monday, May 19th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earningsMay 23, 2025 | marketbeat.comKyverna Therapeutics, Inc. (NASDAQ:KYTX) Given Consensus Rating of "Buy" by AnalystsKyverna Therapeutics, Inc. (NASDAQ:KYTX - Get Free Report) has received an average recommendation of "Buy" from the seven ratings firms that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating aMay 23, 2025 | marketbeat.comQ1 Earnings Forecast for KYTX Issued By HC WainwrightKyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) - Equities researchers at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Kyverna Therapeutics in a note issued to investors on Monday, May 19th. HC Wainwright analyst M. Kapoor forecasts that the company will post eMay 22, 2025 | marketbeat.comSphera Funds Management LTD. Decreases Holdings in Kyverna Therapeutics, Inc. (NASDAQ:KYTX)Sphera Funds Management LTD. trimmed its stake in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) by 52.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 118,758 shMay 18, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Raises Holdings in Kyverna Therapeutics, Inc. (NASDAQ:KYTX)Jacobs Levy Equity Management Inc. boosted its holdings in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) by 2,225.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 461,959 shares of theMay 18, 2025 | marketbeat.comWith 40% ownership, Kyverna Therapeutics, Inc. (NASDAQ:KYTX) has piqued the interest of institutional investorsMay 16, 2025 | finance.yahoo.comKYVERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Kyverna Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmMay 15, 2025 | globenewswire.comKyverna Therapeutics Reports Q1 2025 Progress and OutlookMay 15, 2025 | tipranks.comIntegral Health Asset Management LLC Acquires 150,000 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX)Integral Health Asset Management LLC boosted its holdings in Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) by 75.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 350,000 shares of the company'sMay 14, 2025 | marketbeat.comKyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial ResultsMay 13, 2025 | prnewswire.comKyverna Therapeutics (KYTX) Expected to Announce Earnings on TuesdayKyverna Therapeutics (NASDAQ:KYTX) will be releasing its Q1 2025 earnings before the market opens on Tuesday, May 13. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-13-kyverna-therapeutics-inc-stock/)May 8, 2025 | marketbeat.comKyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Consensus Recommendation of "Buy" from AnalystsShares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Get Free Report) have been assigned a consensus rating of "Buy" from the seven brokerages that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a hold recommendation, five have given a buy recommendatioApril 28, 2025 | marketbeat.comGilead Sciences Inc. Acquires New Position in Kyverna Therapeutics, Inc. (NASDAQ:KYTX)Gilead Sciences Inc. bought a new position in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 4,126,119 shares of the company's stock, valuApril 20, 2025 | marketbeat.comJPMorgan Chase & Co. Trims Holdings in Kyverna Therapeutics, Inc. (NASDAQ:KYTX)JPMorgan Chase & Co. lowered its position in Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) by 9.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,166,437 shares of the company's stock after sApril 17, 2025 | marketbeat.comKyverna Therapeutics, Inc. (NASDAQ:KYTX) Holdings Trimmed by Franklin Resources Inc.Franklin Resources Inc. cut its holdings in Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) by 26.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 692,028 shares of the company's sApril 15, 2025 | marketbeat.comEquities Analysts Offer Predictions for KYTX Q1 EarningsKyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) - Research analysts at HC Wainwright lowered their Q1 2025 earnings per share estimates for shares of Kyverna Therapeutics in a research report issued to clients and investors on Thursday, April 3rd. HC Wainwright analyst M. Kapoor now expectApril 8, 2025 | marketbeat.comHC Wainwright Lowers Kyverna Therapeutics (NASDAQ:KYTX) Price Target to $4.00HC Wainwright decreased their price target on shares of Kyverna Therapeutics from $6.00 to $4.00 and set a "neutral" rating for the company in a research note on Thursday.April 5, 2025 | marketbeat.comKyverna Therapeutics price target lowered to $4 from $6 at H.C. WainwrightApril 4, 2025 | markets.businessinsider.comKyverna Therapeutics price target lowered to $20 from $40 at Morgan StanleyApril 2, 2025 | markets.businessinsider.comKyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Consensus Rating of "Buy" from AnalystsShares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Get Free Report) have received a consensus recommendation of "Buy" from the six brokerages that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold recommendation, four have assigned a buy reApril 2, 2025 | marketbeat.comKyverna Therapeutics (NASDAQ:KYTX) Given New $20.00 Price Target at Morgan StanleyMorgan Stanley decreased their target price on shares of Kyverna Therapeutics from $40.00 to $20.00 and set an "overweight" rating on the stock in a research report on Tuesday.April 2, 2025 | marketbeat.comKyverna Therapeutics price target lowered to $12 from $13 at UBSMarch 29, 2025 | markets.businessinsider.comKyverna Therapeutics sees cash and securities sufficient into 2027March 29, 2025 | markets.businessinsider.comKyverna Therapeutics files $250M mixed securities shelfMarch 29, 2025 | markets.businessinsider.comKyverna Therapeutics Advances CAR T-Cell Therapy TrialsMarch 29, 2025 | tipranks.comKyverna Therapeutics (NASDAQ:KYTX) Announces Earnings Results, Misses Expectations By $0.04 EPSKyverna Therapeutics (NASDAQ:KYTX - Get Free Report) announced its quarterly earnings results on Tuesday. The company reported ($0.88) earnings per share for the quarter, missing analysts' consensus estimates of ($0.84) by ($0.04).March 28, 2025 | marketbeat.comKyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 27, 2025 | prnewswire.comKyverna: 2 Myasthenia Gravis Program Catalysts On Deck In 2025March 21, 2025 | seekingalpha.comKyverna Therapeutics (KYTX) Projected to Post Quarterly Earnings on TuesdayKyverna Therapeutics (NASDAQ:KYTX) will be releasing earnings before the market opens on Tuesday, March 25, Financial Modeling Prep reports.March 18, 2025 | marketbeat.comGRABAR LAW OFFICE INVESTIGATES CLAIMS ON BEHALF OF SHAREHOLDERS OF KYVERNA THERAPEUTICS, INC. (KYTX)March 14, 2025 | markets.businessinsider.comKyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Average Rating of "Buy" from AnalystsShares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Get Free Report) have been assigned an average recommendation of "Buy" from the nine analysts that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating, seven have issued a buy ratingFebruary 13, 2025 | marketbeat.comKYTX stock touches 52-week low at $2.78 amid sharp annual declineFebruary 12, 2025 | msn.comFY2025 Earnings Estimate for KYTX Issued By Leerink PartnrsKyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) - Leerink Partnrs boosted their FY2025 earnings per share (EPS) estimates for Kyverna Therapeutics in a report issued on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now expects that the company will post earnings per share of ($February 10, 2025 | marketbeat.comInvestors in Kyverna Therapeutics, Inc. Should Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights – KYTXFebruary 7, 2025 | globenewswire.comKYTX Deadline: KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities LawsuitFebruary 7, 2025 | prnewswire.comSHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna TherapeuticsFebruary 7, 2025 | prnewswire.comAnalysts Issue Forecasts for KYTX FY2029 EarningsKyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) - Stock analysts at Leerink Partnrs issued their FY2029 earnings per share estimates for Kyverna Therapeutics in a report released on Wednesday, February 5th. Leerink Partnrs analyst T. Smith forecasts that the company will post earnings of (February 7, 2025 | marketbeat.comKyverna Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Kyverna Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 7, 2025 - KYTXFebruary 7, 2025 | prnewswire.comInvestors in Kyverna Therapeutics, Inc. Should Contact The Gross Law Firm Before February 7, 2025 to Discuss Your Rights – KYTXFebruary 6, 2025 | globenewswire.comKYTX DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Kyverna Therapeutics, Inc. Investors to Secure Counsel Before Important February 7 Deadline in Securities Class Action – KYTXFebruary 6, 2025 | globenewswire.comThe Gross Law Firm Reminds Kyverna Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 7, 2025 - KYTXFebruary 6, 2025 | prnewswire.comKyverna Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. February 7, 2025 Deadline to file Lead Plaintiff Motion.February 4, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Kyverna Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - KYTXFebruary 4, 2025 | prnewswire.com Get Kyverna Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYTX and its competitors with MarketBeat's FREE daily newsletter. Email Address KYTX Media Mentions By Week KYTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KYTX News Sentiment▼1.340.88▲Average Medical News Sentiment KYTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KYTX Articles This Week▼27▲KYTX Articles Average Week Get Kyverna Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BCYC News MNMD News DNTH News KURA News MRVI News RLAY News KROS News ARVN News MAZE News TYRA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KYTX) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket ch...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kyverna Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kyverna Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy KYTX Stock Free KYTX Stock Alerts